Yes, this is the same company who, only 3 weeks ago, released another press release signalling their intention to go after, amongst other things, a $22 Billion a year market for autism medication in the US.
Does this mean that CBIS are privy to the results of some kind of ‘Cannabis extracts for autism’ trial, not yet revealed to the public in general? Or were they just going along with the ‘rumour’ that cannabis ‘may’ treat autism and hoping they’ll pan out the real gold later?
It does make you wonder, doesn’t it? There are 15 medical areas being targeted by CBIS extracts. Of those, nearly all have decent research behind them. Of those that do, they all have one thing in common: People were right about cannabis treating their conditions. Critics were silenced, the cannabis was not causing delusions of recovery or remission.
Sadly, no-one applies this logic to cannabis for autism. Despite never being true for any other medical condition, people still try to suggest that cannabis is not really treating autism, and that the autistic people, their families, their doctors and their friends are all deluded by cannabis.
Investors: If you were to put money on whether or not cannabis treats autism, given the available data on all cannabis-treatable conditions, would you or not?
I think maybe you would 😉